Infectious Enteritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, Injectables), By Drug Type (Antibiotics, Antivirals, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 512.21 Million
CAGR (2026-2031)	7.53%
Fastest Growing Segment	Oral
Largest Market	North America
Market Size (2031)	USD 791.82 Million

Market Overview

The Global Infectious Enteritis Treatment Market will grow from USD 512.21 Million in 2025 to USD 791.82 Million by 2031 at a 7.53% CAGR. Infectious enteritis treatment encompasses pharmacotherapies, such as antibiotics and antivirals, alongside rehydration regimens aimed at managing intestinal inflammation caused by pathogenic microorganisms. Market growth is fundamentally supported by the rising incidence of diarrheal diseases globally and increased investments in healthcare infrastructure which expand access to essential medicines. According to the World Health Organization, in 2025, reported global cholera cases increased by 5% in 2024 compared to the previous year, underscoring the persistent need for effective therapeutic interventions. This growing disease burden ensures sustained demand for established treatment modalities across affected regions.

A significant challenge impeding market expansion is the escalating issue of antimicrobial resistance among enteric pathogens. The proliferation of multidrug-resistant bacterial strains renders standard antibiotic courses less effective, complicating clinical outcomes and necessitating complex treatment protocols. This resistance forces pharmaceutical developers to incur high costs in researching alternative therapies, creating substantial regulatory and economic hurdles that restrict market accessibility and growth.

Key Market Drivers

The increasing global prevalence of foodborne and waterborne enteric infections acts as a primary catalyst for market demand. As pathogens such as Norovirus, Salmonella, and Listeria continue to spread due to hygiene challenges and complex supply chains, the requirement for effective therapeutics escalates significantly. According to the United Kingdom Health Security Agency, April 2024, in the 'National Norovirus and Rotavirus Report', reported norovirus laboratory reports were 75% higher than the five-year average, highlighting the volatility and rapid spread of enteric outbreaks. This surge in infection rates necessitates robust supply chains for rehydration salts and symptom-management drugs to mitigate widespread morbidity. Furthermore, according to the Centers for Disease Control and Prevention, in 2024, a severe multistate outbreak of Listeria monocytogenes linked to deli meats resulted in 57 hospitalizations, reinforcing the critical need for potent antibiotic interventions and hospital-grade therapies for severe foodborne cases.

Concurrently, a surge in research and development investments for novel antimicrobial and antiviral therapies is reshaping the competitive landscape. To combat the declining efficacy of traditional antibiotics against resistant bacterial strains, public and private entities are channeling capital into discovering next-generation treatments. According to the United Kingdom Government, May 2024, in the 'Antimicrobial Resistance Funding Announcement', a commitment of £85 million was allocated specifically to support research into antimicrobial resistance and the development of new treatments for infectious diseases. These financial injections allow pharmaceutical companies to accelerate clinical trials and overcome regulatory hurdles associated with novel drug approval. This influx of funding not only mitigates the financial risk of development but also ensures a pipeline of advanced therapeutic options remains available to address evolving pathogenic threats.

Download Free Sample Report

Key Market Challenges

The escalating prevalence of antimicrobial resistance presents a formidable barrier to the expansion of the infectious enteritis treatment market. As enteric pathogens increasingly withstand standard antibiotic regimens, the clinical utility of existing pharmacotherapies diminishes, forcing pharmaceutical developers to invest heavily in the discovery of novel compounds. This shift necessitates complex and costly research initiatives that carry a high risk of failure, thereby squeezing profit margins and discouraging new market entrants. The financial burden of developing alternative therapies creates a restrictive economic environment that directly hampers the commercial scalability of treatment portfolios.

This challenge is substantiated by recent surveillance data indicating the severity of the issue. According to the European Centre for Disease Prevention and Control, in 2024, the proportion of Campylobacter coli isolates resistant to ciprofloxacin in humans was reported at 65.7% across reporting countries. Such high resistance rates accelerate the obsolescence of frontline treatments, reducing the viable lifespan of current inventory. Consequently, the market faces a continuous cycle of product devaluation, which impedes long-term revenue growth and complicates the strategic planning required to maintain a stable supply of effective medicines.

Key Market Trends

The market is witnessing a paradigmatic shift towards microbiome-modulating therapeutics, particularly for addressing recurrent Clostridioides difficile infections that often follow standard antibiotic treatments. Unlike traditional antimicrobials that disrupt gut ecology, these live biotherapeutic products are designed to restore the intestinal microbial community, thereby preventing pathogen recolonization and breaking the cycle of recurrence. This adoption is commercially validated by the performance of the first FDA-approved oral microbiome therapy, which has seen immediate traction among gastroenterologists seeking alternatives to standard care. According to Seres Therapeutics, May 2024, in the 'First Quarter 2024 Financial Results', net sales for their microbiome therapeutic VOWST reached $10.1 million in the first quarter of 2024, reflecting a rapid uptake in clinical settings. This trajectory highlights the growing reliance on biological restoration strategies to manage complex enteritis cases where standard pharmacotherapy fails.

Concurrently, clinical management is being revolutionized by the integration of rapid point-of-care molecular diagnostics, which replace time-consuming culture methods with syndromic panel testing. These advanced platforms enable healthcare providers to simultaneously detect a broad spectrum of viral, bacterial, and parasitic pathogens from a single stool sample, significantly reducing the time required for diagnosis and facilitating targeted, narrow-spectrum treatment. The commercial expansion of these diagnostic panels evidences their critical role in modernizing enteritis care protocols. According to bioMérieux, September 2024, in the 'First-Half 2024 Results', sales of BIOFIRE non-respiratory panels, which include gastrointestinal testing solutions, grew by 19% organically in the first half of the year. This widespread implementation supports a more precise therapeutic approach, minimizing unnecessary antibiotic use and optimizing patient isolation protocols.

Segmental Insights

The oral segment is projected to emerge as the fastest-growing category within the Global Infectious Enteritis Treatment Market due to enhanced patient adherence and ease of administration. This growth is largely driven by the strong advocacy from the World Health Organization regarding oral rehydration therapy and zinc supplements as the primary standard of care for acute diarrhea. Additionally, manufacturers are increasing the production of oral antibiotics and vaccines to address the high prevalence of enteric infections in developing regions. Consequently, the preference for non-invasive treatments over intravenous options continues to accelerate market expansion for this segment.

Regional Insights

North America maintains a leading position in the global infectious enteritis treatment market due to its well-developed healthcare sector and the concentrated presence of key pharmaceutical companies. The region benefits from rigorous disease surveillance systems managed by organizations like the Centers for Disease Control and Prevention, which facilitate timely diagnosis of bacterial and viral infections. Additionally, the United States Food and Drug Administration supports market growth through structured regulatory pathways for new drug approvals. These factors, alongside accessible reimbursement frameworks, ensure consistent demand for therapeutics throughout the United States and Canada.

Recent Developments

• In August 2024, Valneva SE entered into a strategic partnership and exclusive licensing agreement with LimmaTech Biologics AG to advance the development of a vaccine for shigellosis. The collaboration focused on Shigella4V, a tetravalent bioconjugate vaccine candidate intended to prevent invasive dysentery caused by the Shigella bacterium. Under the terms of the deal, Valneva obtained global rights to develop, manufacture, and commercialize the candidate, paying LimmaTech an upfront fee of €10 million. This agreement marked a significant step in addressing a leading cause of fatal diarrheal disease, particularly affecting children in low- and middle-income countries and international travelers.
• In July 2024, HilleVax, Inc. reported topline data from its Phase 2b clinical trial evaluating the efficacy of HIL-214, a virus-like particle vaccine candidate for norovirus. The study, which enrolled infants in the United States and Latin America, failed to meet its primary endpoint of preventing moderate-to-severe acute gastroenteritis caused by specific norovirus genotypes. Consequently, the company announced the discontinuation of further development of the vaccine for the pediatric population. This event highlighted the significant challenges in developing effective prophylactic treatments for norovirus, a major pathogen in the infectious enteritis landscape, although the company continued to explore potential applications for adults.
• In April 2024, the World Health Organization (WHO) granted prequalification to Euvichol-S, a new oral cholera vaccine produced by EuBiologics Co., Ltd. This simplified formulation of the company’s existing vaccine was designed to streamline manufacturing processes and increase production capacity to meet surging global demand. The approval followed a successful Phase 3 clinical trial demonstrating that the vaccine remained equally effective against key cholera serogroups while lowering production costs. This development was critical for the Global Infectious Enteritis Treatment Market, as it aimed to alleviate severe shortages in the global stockpile used to combat outbreaks of this acute diarrheal infection.
• In April 2024, Vaxart, Inc. announced positive topline results from a Phase 1 clinical trial evaluating its oral bivalent norovirus vaccine candidate in lactating mothers. The study demonstrated that the oral pill vaccine successfully induced a robust mucosal immune response, significantly increasing norovirus-specific antibodies in the breast milk of participants. This breakthrough research suggested a potential pathway for providing passive immunity to infants against norovirus, a leading cause of viral gastroenteritis. The company highlighted that the oral tablet platform offered a unique approach to addressing infectious enteritis by generating mucosal immunity in the gastrointestinal tract, where such infections primarily occur.

Key Market Players

• Novartis AG
• Gilead Sciences Inc
• GlaxoSmithKline plc
• Janssen Global Services, LLC
• F. Hoffmann-La Roche Ltd.
• BioCryst Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH
• Sanofi A.G.
• Medtronic Plc.

By Route of Administration	By Drug Type	By Region
Oral Injectables	Antibiotics Antivirals Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Infectious Enteritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Infectious Enteritis Treatment Market, By Route of Administration:

• Oral
• Injectables

• Infectious Enteritis Treatment Market, By Drug Type:

• Antibiotics
• Antivirals
• Others

• Infectious Enteritis Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE